Indications and uses
Helps prevent sunburn
LBEL FILLING EFFECT FOUNDATION SPF 10
- Manufacturer
- Ventura International LTD | Bel Star S.A. (Colombia)
- Effective date
- 2013-12-19
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:37:51
Label at a glance#
ProductLBEL FILLING EFFECT FOUNDATION SPF 10 (CLAIRE 1) - BEIGE
Active ingredientOctinoxate
Label structure19 sections
Dosage and administration
Apply liberally and evenly 15 minutes before sun exposure. Reapply at least every 2 hours Use a water resistant sunscreen if swimming or sweating. Children under 6 months of age: Ask a doctor
Storage and handling
Protect the product in this container from excessive heat and direct sun.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active Ingredients
Octinoxate 7 %
Purpose
Sunscreen
Uses
- Helps prevent sunburn
Warnings
SPL UNCLASSIFIED SECTION
- Skin Cancer / Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging.This product has been shown only to help prevent sunburn, not skin cancer or early skin aging.
- For external use only.
OTC - DO NOT USE SECTION
- Do not use on damaged or broken skin.
OTC - WHEN USING SECTION
- When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
- Stop use and ask a doctor if rash occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- Apply liberally and evenly 15 minutes before sun exposure.
- Reapply at least every 2 hours
- Use a water resistant sunscreen if swimming or sweating.
- Children under 6 months of age: Ask a doctor
Other information
- Protect the product in this container from excessive heat and direct sun.
Inactive ingredients
AQUA (WATER), CYCLOMETHICONE, CYCLOPENTASILOXANE, CYCLOHEXASILOXANE, SODIUM CHLORIDE, PEG/PPG-18/18 DIMETHICONE, DIMETHICONE, NYLON-12 FLUORESCENT BRIGHTENER 230 SALT, DIMETHICONOL, DIAZOLIDINYL UREA, CETEARYL DIMETHICONE CROSSPOLYMER, METHYLPARABEN, PARFUM (FRAGRANCE), PROPYLPARABEN, POLYVINYLALCOHOL CROSSPOLYMER, SODIUM HYALURONATE.
MAY CONTAIN
TITANIUM DIOXIDE (CI 77891), IRON OXIDES (CI 77492), IRON OXIDES (CI 77499), IRON OXIDES (CI 77491), METHICONE
SPL UNCLASSIFIED SECTION
Distributed by Ventura International Ltd. DBA Belcorp USA, San Francisco, CA 94111
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Claire 1) - Beige
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Claire 2) - Beige
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Claire 3) - Beige
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Claire 4) - Beige
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Medium 5) - Brown
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Medium 6) - Brown
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Medium 7) - Brown
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Obscure 8) - Brown
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Bottle Box - (Obscure 9) - Brown
L'BEL
EFFET
PARFAIT
filling effect
foundation SPF 10
30 ml e (1 fl.oz.)
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| cyclomethicone | INACTIVE INGREDIENT | NMQ347994Z | 1 | |
| cyclomethicone 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| cyclomethicone 6 | INACTIVE INGREDIENT | XHK3U310BA | 1 | |
| diazolidinyl urea | INACTIVE INGREDIENT | H5RIZ3MPW4 | 1 | |
| dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| ferric oxide red | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| ferric oxide yellow | INACTIVE INGREDIENT | EX438O2MRT | 1 | |
| ferrosoferric oxide | INACTIVE INGREDIENT | XM0M87F357 | 1 | |
| hyaluronate sodium | INACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| peg/ppg-18/18 dimethicone | INACTIVE INGREDIENT | 9H0AO7T794 | 1 | |
| propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| sodium chloride | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- LBEL FILLING EFFECT FOUNDATION SPF 10 (CLAIRE 1) - BEIGE
- Octinoxate
- water
- cyclomethicone
- cyclomethicone 5
- cyclomethicone 6
- sodium chloride
- peg/ppg-18/18 dimethicone
- dimethicone
- diazolidinyl urea
- methylparaben
- propylparaben
- hyaluronate sodium
- titanium dioxide
- ferric oxide yellow
- ferrosoferric oxide
- ferric oxide red
- LBEL FILLING EFFECT FOUNDATION SPF 10 (CLAIRE 2) - BEIGE
- LBEL FILLING EFFECT FOUNDATION SPF 10 (CLAIRE 3) - BEIGE
- LBEL FILLING EFFECT FOUNDATION SPF 10 (CLAIRE 4) - BEIGE
- LBEL FILLING EFFECT FOUNDATION SPF 10 (MEDIUM 5) - BROWN
- LBEL FILLING EFFECT FOUNDATION SPF 10 (MEDIUM 6) - BROWN
- LBEL FILLING EFFECT FOUNDATION SPF 10 (MEDIUM 7) - BROWN
- LBEL FILLING EFFECT FOUNDATION SPF 10 (OBSCURE 8) - BROWN
- LBEL FILLING EFFECT FOUNDATION SPF 10 (OBSCURE 9) - BROWN
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | POWDER, FOR SUSPENSION / ORAL | 3 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CONCENTRATE / ORAL | 12 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, FILM COATED / ORAL | 6 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / INTRAMUSCULAR | 0.02 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAMUSCULAR | 90 mg | ||
| cyclomethicone | CYCLOMETHICONE | NMQ347994Z | LOTION / TOPICAL | 3510 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBARACHNOID | 0.9 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CAPSULE, EXTENDED RELEASE / ORAL | 2 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRA-ARTERIAL | 278 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRATHECAL | 131 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | TABLET, EXTENDED RELEASE / ORAL | 0.12 mg | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | TABLET, COATED / ORAL | 1 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | LOTION / TOPICAL | 140 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | LIQUID / TOPICAL | 0.1 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / IONTOPHORESIS | 0.6 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / EPIDURAL | 1 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER, DENTIFRICE / DENTAL | 0.03 mg/mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / OPHTHALMIC | 13 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER / TOPICAL | NA | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1800 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INHALANT / RESPIRATORY (INHALATION) | 3 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SOFT TISSUE | 0.02 %w/v | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, EXTENDED RELEASE / ORAL | 5 mg | ||
| ferrosoferric oxide | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, FILM COATED / ORAL | 0.2 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | JELLY / NASAL | 140 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / TOPICAL | 0.24 %w/v | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INFILTRATION | 0.35 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SHAMPOO, SUSPENSION / TOPICAL | 3 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| hyaluronate sodium | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / OPHTHALMIC | 0.05 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SYSTEM / TOPICAL | 3.1 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | INSERT, EXTENDED RELEASE / OPHTHALMIC | 0.4 mg | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, DELAYED RELEASE / ORAL | 14 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2922 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ORAL | 98 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SUBCUTANEOUS | 2 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAMUSCULAR | 0.13 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTICULAR | 26 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE, EXTENDED RELEASE / ORAL | 41 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 3586c723-ee81-45b0-e063-6394a90a0e73 | ef3f31f2-506f-4797-8303-702a33d72d05 | 2025-05-19 | Warnings | ef3f31f2-506f-4797-8303-702a33d72d05 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.